Lindsey Shapiro, PhD, science writer —

Lindsey earned her PhD in neuroscience from Emory University in Atlanta, where she studied novel therapeutic strategies for treatment-resistant forms of epilepsy. She was awarded a fellowship from the American Epilepsy Society in 2019 for this research. Lindsey also previously worked as a postdoctoral researcher, studying the role of inflammation in epilepsy and Alzheimer’s disease.

Articles by Lindsey Shapiro

Sustained gains with long-term Vyvgart use seen in ADAPT+ trial

Repeat cycles of Vyvgart (efgartigimod alfa-fcab) led to consistent clinical improvements among generalized myasthenia gravis (gMG) patients, regardless of whether they were positive for antibodies against the acetylcholine receptor, according to interim findings from the ADAPT+ extension study. Given the variability in how many treatment cycles each patient…

Rystiggo, Zilbrysq earn EU approvals for adults with gMG

The European Commission has approved Rystiggo (rozanolixizumab) as an add-on to standard therapy for the treatment of certain adults with generalized myasthenia gravis (gMG), closely following its clearance of Zilbrysq (zilucoplan) as an add-on treatment last month. These medications are sold by the biopharma company UCB.

European panel recommends under-the-skin efgartigimod for gMG

A European Medicines Agency (EMA) committee has recommended the approval of Argenx’s under-the-skin, or subcutaneous, formulation of efgartigimod as an add-on to standard therapy for adults with generalized myasthenia gravis (gMG) who have antibodies against acetylcholine receptors (AChRs). Argenx’s into-the-vein (intravenous) formulation of efgartigimod, sold as Vyvgart,…

Cell-based assay better at detecting MG-driving antibodies

A cell-based assay for detecting myasthenia gravis (MG)-causing antibodies in the blood results in greater diagnostic accuracy than two other antibody tests, according to data from a study in China. The cell-based assay (CBA) was superior to enzyme-linked immunoabsorbent assay (ELISA) and radioactivity radioimmunoprecipitation assay (RIPA) at detecting antibodies…